RxDoctor Payments Data

Babu Patel, MD

Internal Medicine · Bronx, NYNPI 1689654220

Payments from drug & device makers

$1,291in general payments, 2019–2025

Across 24 payments — averaging $53.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$287
  • Otsuka America Pharmaceutical, Inc.$266
  • Boehringer Ingelheim$138
  • Teva Pharmaceuticals USA, Inc.$125
  • Viatris Specialty LLC$125
  • Avanir Pharmaceuticals, Inc.$115
  • plus $235 from 6 others

What the payments were for

  • Food & beverage$1,291100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,291 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$19,551
Medicare patients
35
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate300$227,305
JanumetSitagliptin Phos/Metformin Hcl250$194,044
EliquisApixaban182$132,345
OzempicSemaglutide90$89,371
FarxigaDapagliflozin Propanediol105$82,518
TrulicityDulaglutide69$82,406
EntrestoSacubitril/Valsartan55$50,950
JardianceEmpagliflozin54$47,733
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$43,392
Tresiba Flextouch U-200Insulin Degludec41$34,050
RestasisCyclosporine46$31,521
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog71$29,731
TradjentaLinagliptin30$27,094
Breo ElliptaFluticasone/Vilanterol54$24,992
LinzessLinaclotide29$21,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$287$89,37190 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$138$83,31795 claims
Lilly USA, LLCTrulicity$16$82,40669 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$30$51,25491 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →